<DOC>
	<DOCNO>NCT00002119</DOCNO>
	<brief_summary>To evaluate clinical toxicity , safety , MTD WF 10 ( TCDO ) intravenous solution administer patient HIV infection . To evaluate potential anti-HIV activity TCDO .</brief_summary>
	<brief_title>A Phase I/II Clinical Study WF 10 IV Solution ( TCDO ) Patients With HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Aerosolized pentamidine ( 300 mg monthly ) prophylaxis PCP patient CD4 count &lt; = 200 cells/mm3 . Allowed : PCP prophylaxis aerosolized pentamidine patient CD4 count &gt; 200 cells/mm3 , discretion treat physician . Patients must : HIV positivity . Absolute CD4 count 150 500 cells/mm3 . At least 6 month prior zidovudine therapy . No active opportunistic infection require ongoing therapy . Life expectancy least 6 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Neoplasm basal cell carcinoma skin . Clinically significant cardiac disease . Abnormal neurological status standardize assessment include strength , reflex testing , sensory testing . Unwilling comply protocol requirement . Patients follow prior condition exclude : History myocardial infarction arrhythmia . Prior Medication : Excluded within 2 week prior study entry : Antiretroviral agent interferon . Systemic biologic response modifier , corticosteroid , cytotoxic chemotherapeutic agent , drug cause neutropenia significant nephrotoxicity . Rifampin rifampin derivative . Systemic antiinfectives . Required : At least 6 month prior zidovudine . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>